Dan Theodorescu, MD, PhD
Dan Theodorescu MD Ph.D. is the Director of the Samuel Oschin Comprehensive Cancer Institute and Cedars-Sinai Cancer enterprise in Los Angeles. From 2010 until 2018, he was Director of the University of Colorado Cancer Center and a Distinguished University Professor. Dr. Theodorescu is known for his work on the molecular mechanisms underlying bladder cancer and tools that determine drug response as well as the discovery of new drugs for cancer. Examples include the discovery of genes that regulate tumor growth and metastasis and novel biomarkers and concepts for precision therapeutic approaches such as the COXEN principle, that are currently being tested in national (SWOG 1314) clinical trials. He also conceptualized the approach and then led the discovery and development of a “first in class” RalGTPase inhibitor as a new therapeutic in cancer. This drug was awarded a US patent and is in commercial development. Most recently he identified approaches that define effective combination therapy with checkpoint inhibitors.
More Information on Theodorescu laboratory can be found at www.cedars-sinai.edu/Research/Research-Labs/Theodorescu-Lab
Theodorescu is the founding co-editor in chief of Bladder Cancer, the first journal focused on this disease and an elected member of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP), the American Association of Genitourinary Surgeons (AAGUS), the American Surgical Association (ASA) and the National Academy of Medicine (NAM). He also serves on the Board of Scientific Counsellors of the National Cancer Institute (NCI) of the United States of America.